James F. Dougherty

James F. Dougherty

Auto-generated profile, based on publicly available information

James F. Dougherty

Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
TP53 is the most frequently mutated gene in cancer, yet key target genes for p53-mediated tumor suppression remain unidentified. Here, we characterize a rare, African-specific germline variant of TP53 in the DNA-binding domain Tyr107His (Y107H). Nuclear magnetic resonance and crystal structures reveal that Y107H is structurally similar to wild-type p53. Consistent with this, we find that Y107H can suppress tumor colony formation and is impaired for the transactivation of only a small subset of p53 target genes; this includes the epigenetic modifier PADI4, which deiminates arginine to the nonnatural amino acid citrulline. Surprisingly, we show that Y107H mice develop spontaneous cancers and metastases and that Y107H shows impaired tumor suppression in two other models. We show that PADI4 is itself tumor suppressive and that it requires an intact immune system for tumor suppression. We identify a p53–PADI4 gene signature that is predictive of survival and the efficacy of immune-checkpoint inhibitors. Significance: We analyze the African-centric Y107H hypomorphic variant and show that it confers increased cancer risk; we use Y107H in order to identify PADI4 as a key tumor-suppressive p53 target gene that contributes to an immune modulation signature and that is predictive of cancer survival and the success of immunotherapy. See related commentary by Bhatta and Cooks, p. 1518. This article is highlighted in the In This Issue feature, p. 1501

7 July 2023
Verified
Other
Open access
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
Extra crystallographic data for p53Y107H.

7 July 2023
Verified
Other
Open access
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
Oligos for ChIP-qPCR and qPCR used in this study

16 June 2023
Verified
Other
Open access
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.

7 July 2023
Verified
Other
Open access
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.

7 July 2023
Verified
Other
Open access
AIAlexandra Indeglia
Alexandra Indeglia
JLJessica C. Leung
Jessica C. Leung
SMSven A. Miller
Sven A. Miller
JLJulia I-Ju Leu
Julia I-Ju Leu
JDJames F. Dougherty
James F. Dougherty
MMMaureen E. Murphy
Maureen E. Murphy
Extra crystallographic data for p53Y107H.